Shares of drug firms Cipla and Lupin surged in morning trade on the bourses today after news reports surfaced that Japan's biggest drug-maker, Takeda Pharmaceutical Co, is in talks to buy either of their pharma businesses.
Cipla opened on a bullish note at Rs 283.90 on the Bombay Stock Exchange and then rose by 1.84% to Rs 287.75. On the National Stock Exchange, the stock opened at Rs 283 and then rallied to a high of Rs 287.60, up 1.91% from its last close.
In a similar fashion, shares of Lupin reacted positively to the news, surging by 4.47% to a high of Rs 457.40 on the BSE and rising by 3.37% to Rs 452.80 on the NSE.
Marketmen said the surge in the stocks was largely due to news reports that Takeda has begun talks with both drug-makers.
As per the report, Takeda is very keen on a large buy-out in the country, but there is no certainty that the talks will lead to a conclusive deal.
The surge in both counters was in sharp contrast to the sentiment in the broader market, with the benchmark indices trading in negative terrain.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
